title: Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
authors: E
authors: E
authors: Piscolla
authors: B
authors: B
authors: Hakiki
authors: L
authors: L
authors: Pastò
authors: L
authors: L
authors: Razzolini
authors: E
authors: E
authors: Portaccio
authors: M P
authors: MP
authors: Amato
mesh_terms: D017668:Age of Onset; D001921:Brain / Q000473:pathology; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010951:Plasma Exchange; D011409:Propylene Glycols / Q000009:adverse effects*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D003520:Cyclophosphamide; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine
references: Neurology. 2008 Mar 25;70(13 Pt 2):1150-1
references: 17872364
references: Neurology. 2011 Nov 22;77(21):1887-95
references: 22076543
references: J Neurol. 2013 Jan;260(1):327-9
references: 23161460
references: Arch Neurol. 2012 Feb;69(2):262-4
references: 22332194
references: Neurology. 2011 May 31;76(22):1858-65
references: 21543733
references: Ther Adv Neurol Disord. 2009 Nov;2(6):50-61
references: 21180630
references: Mult Scler. 2012 Nov;18(11):1636-9
references: 22829326